Functional interrogation and therapeutic targeting of protein tyrosine phosphatases
- 25 August 2021
- journal article
- review article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 49 (4) , 1723-1734
Abstract
Protein tyrosine phosphatases (PTPs) counteract the enzymatic activity of protein tyrosine kinases to modulate levels of both normal and disease-associated protein tyrosine phosphorylation. Aberrant activity of PTPs has been linked to the progression of many disease states, yet no PTP inhibitors are currently clinically available. PTPs are without a doubt a difficult drug target. Despite this, many selective, potent, and bioavailable PTP inhibitors have been described, suggesting PTPs should once again be looked at as viable therapeutic targets. Herein, we summarize recently discovered PTP inhibitors and their use in the functional interrogation of PTPs in disease states. In addition, an overview of the therapeutic targeting of PTPs is described using SHP2 as a representative target.Keywords
This publication has 84 references indexed in Scilit:
- Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5Journal of Clinical Investigation, 2013
- Protein tyrosine phosphatases – from housekeeping enzymes to master regulators of signal transductionThe FEBS Journal, 2012
- Dual‐specificity MAP kinase phosphatases (MKPs)The FEBS Journal, 2012
- Molecular mechanisms of the PRL phosphatasesThe FEBS Journal, 2012
- Regulation and dysregulation of fibrosis in skeletal muscleExperimental Cell Research, 2010
- Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and ProgressionCancer Research, 2010
- Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agentsProceedings of the National Academy of Sciences, 2010
- Protein tyrosine phosphatases: from genes, to function, to diseaseNature Reviews Molecular Cell Biology, 2006
- Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancerBritish Journal of Cancer, 2006
- LMW-PTP Is a Negative Regulator of Insulin-Mediated Mitotic and Metabolic SignallingBiochemical and Biophysical Research Communications, 1997